<DOC>
	<DOCNO>NCT00733876</DOCNO>
	<brief_summary>The purpose trial determine administration allogeneic MSCs define dos safe patient high risk develop significant Acute Kidney Injury ( AKI ) undergo on-pump cardiac surgery .</brief_summary>
	<brief_title>Allogeneic Multipotent Stromal Cell Treatment Acute Kidney Injury Following Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Kidney Tubular Necrosis , Acute</mesh_term>
	<criteria>Documented ischemic coronary heart and/or valvular heart disease : Acceptable candidate elective CABG and/or Cardiac Valve Surgery Patients high risk postop AKI : Age 18 old high risk postop AKI underlie Diabetes mellitus ( type I II ) , CHF , COPD Chronic Kidney Disease ( CKD ) stage 14 Patients high risk postop AKI : age &gt; 65 combination Patent femoral artery without aortic aneurysm Ability give inform consent . Presence ongoing local systemic infection Younger 18 Participation another clinical trial Pregnancy Contraindication general anesthesia Prisoner Dialysis patient ( CKD6 ) patient CKD5 History malignancy except nonmelanoma skin cancer Occluded Groin artery Uncontrolled Diabetes mellitus ( HbA1c &gt; 10 , history diabetic ketoacidosis osmolar coma within last three month ) Nonhealing foot ulcer . Clinical evidence severe peripheral vascular disease ( ABI &lt; 0.3 ) Coronary Angiogram &lt; 7 day surgery Inadequate preoperative time obtain baseline kidney function data due urgent/emergent surgery Unstable myocardium ( evolve myocardial infarction ) , cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Acute Renal Failure Cardiac Surgery Stem Cell</keyword>
</DOC>